NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

Technology Appraisal [Committee A] meeting minutes

**Minutes:** Confirmed

**Date and time:** Tuesday 2 November 2021 09:00am – 17:00

**Location:** Zoom video Conference

# Committee members present

1. Dr Jane Adam [Chair] Present for all items
2. Dr Brian Shine [Vice Chair] Present for all items
3. Dr Craig Buckley Present for all items
4. Dr Andrew Champion Present for all items
5. Dr David Maudgil Present for all items
6. Dominic Pivonka Present for all items
7. Dr Fiona MacPherson Present for all items

Smith

1. Professor G.J Mendelez- Present for items 1 to 4.3.2 as a committee member,

Torres and 5 to 5.1.4 as an ERG representative

1. Mr Hugo Pedder Present for all items
2. Dr Justin Daniels Present for items 1 to 3.2.2
3. Dr Michael Holmes Present for items 1 to 3.2.2
4. Mr Richard Ballerand Present for items 1 to 3.2.2
5. Dr Rita Faria Present for all items
6. Dr Steve Edwards Present for all items
7. Ms Ana Duarte Present for all items
8. Dr Mohit Sharma Present for all items
9. Mr Alan Thomas Present for all items
10. Min Ven Teo Present for items 5 to 5.1.4

# NICE staff present:

James Devine, Coordinator Present for all items

Catherine Pank, Assistant Present for all items

project manager

Natalie Spray, Programme Present for all items

manager

Shonagh D’Sylva, Project Present for items 1 to 3.2.2

manager

Thomas Feist, Project Present for items 4 to 5.2.2

manager

Henry Edwards, Associate Present for items 1 to 3.2.2

director

Janet Robertson, Associate Present for items 4 to 5.1.4

director

Eleanor Donegan, Technical Present for items 1 to 3.2.2

advisor

Luke Cowie, Technical Present for items 1 to 3.2.2

analyst

Carl Prescott, Technical Present for items 4 to 4.3.2

advisor

Jeremy Dietz, Technical Present for items 4 to 4.3.2

analyst

Mary Hughes, Technical Present for items 5 to 5.1.4

advisor

Albany Meikle, Technical Present for items 5 to 5.1.4

analyst

Lucy Ingram, Technology Present for items 1 to 3.2.2

appraisals administrator

Marcia Miller, Technology Present for all items

appraisals administrator

Laura Marsden, PIP Present for all items

representative

Sandra M Robinson, Assistant Present for items 4 to 4.3.2

project manager

Michelle Green, Technical Present for items 4 to 4.3.2

advisor

Sarah Bromley, Editor Present for items 4 to 4.3.2

# External group representatives present:

Yen-Fu Chen, Warwick Present for items 1 to 3.2.2

evidence

Ewen Cummins, Warwick Present for items 1 to 3.2.2

evidence

James Mahon, LRiG Present for items 4 to 4.3.2

Sophie Beale, LriG Present for items 4 to 4.3.2

G.J. Mendelez-Torres, PenTAG Present for items 5 to 5.1.4

Brian O’Toole, PenTAG Present for items 5 to 5.1.4

# Clinical & patient experts present:

Professor Peter Clark, NHS Present for all items

England CDF Lead

Dr Susan Banerjee, Clinical Present for items 1 to 3.2.2

expert

Dr Andrew Clamp, Clinical Present for items 1 to 3.2.2

expert

Hilary Maxwell, Patient expert Present for items 1 to 3.1.3

Sharon McCartney, Patient Present for items 1 to 3.1.3

expert

Professor Paul Lorigan, Present for items 4 to 4.1.4

Clinical expert

Dr Sophia Papa, Clinical expert Present for items 4 to 4.1.4

Ms Diane Cannon, Patient Present for items 4 to 4.3.2

expert

Dr Beth Phillips, Clinical Present for items 5 to 5.1.4

expert

Dr Graham Collins, Clinical Present for items 5 to 5.1.4

expert

1. Introduction to the meeting
   1. The chair welcomed members of the committee and other attendees present to the meeting.
2. News and announcements
   1. None.
3. Appraisal of Dostarlimab for previously treated advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency [ID3802]
   1. Part 1 – Open session
      1. The chair welcomed the invited clinical and patient experts, external group representatives, members of the public and company representatives from GlaxoSmithKline
      2. The chair asked all committee members, clinical and patient experts, external group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.

* No conflicts of interest were declared for this topic
  + 1. The Chair/Vice Chair then introduced the lead team Ms Ana Duarte (cost lead), Dr Justin Daniels (clinical lead), and Mr Richard Ballerand (lay lead), who gave presentations on the clinical effectiveness and cost effectiveness of Dostarlimab for previously treated advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency [ID3802]
  1. Part 2 – Closed session [company representatives, clinical and patient experts, external group representatives and members of the public were asked to leave the meeting]
     1. The committee then agreed on the content of the Appraisal Consultation Document [ACD] or Final Appraisal Determination [FAD]. The committee decision was reached by consensus..
     2. The committee asked the NICE technical team to prepare the Appraisal Consultation Document [ACD] or Final Appraisal Determination [FAD] in line with their decisions.

A document summarising the recommendations and committee’s considerations will be available here:

https://www.nice.org.uk/guidance/ta685

1. Appraisal of Pembrolizumab for adjuvant treatment of resected melanoma with high risk of recurrence (CDF Review of TA553) [ID3776]
   1. Part 1 – Open session
      1. The chair welcomed the invited clinical and patient experts, external group representatives, members of the public and company representatives from Merck
      2. The chair asked all committee members, clinical and patient experts, external group representatives and NICE staff present to declare any relevant interests in relation to the item being considered  
           
         No conflicts of interest were declared for this item.
      3. The Chair/Vice Chair then introduced the lead team Dominic Pivonka (cost lead), Andrew Champion (clinical lead) and Richard Ballerand (lay lead), who gave presentations on the clinical effectiveness and cost effectiveness of Pembrolizumab for adjuvant treatment of resected melanoma with high risk of recurrence (CDF Review of TA553) [ID3776]
   2. Closed session [company representatives, clinical and patient experts, external group representatives and members of the public were asked to leave the meeting].
      1. The committee then agreed on the content of the Appraisal Consultation Document [ACD] or Final Appraisal Determination [FAD]. The committee decision was reached by consensus..
      2. The committee asked the NICE technical team to prepare the Appraisal Consultation Document [ACD] or Final Appraisal Determination [FAD] in line with their decisions.

A document summarising the recommendations and committee’s considerations will be available here:

https://www.nice.org.uk/guidance/indevelopment/gid-ta10844/documents

1. Evaluation of Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma after stem cell transplant or at least 2 previous therapies [ID1557]
   1. Part 1 – Open session
      1. The chair welcomed the invited clinical and patient experts, external group representatives, members of the public and company representatives from Merck.
      2. The chair asked all committee members, clinical and patient experts, external group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.

* No conflicts of interest were declared for this appraisal
  + 1. The Chair/Vice Chair then introduced the lead team Becky Pennington (cost lead), Alice Turner (clinical lead), and Pamela Mary Rees (lay lead), who gave presentations on the clinical effectiveness and cost effectiveness of Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma after stem cell transplant or at least 2 previous therapies [ID1557]
    2. The committee then agreed on the content of the Appraisal Consultation Document [ACD] or Final Appraisal Determination [FAD]. The committee decision was reached by consensus..
    3. The committee asked the NICE technical team to prepare the Appraisal Consultation Document [ACD] or Final Appraisal Determination [FAD] in line with their decisions.

A document summarising the recommendations and committee’s considerations will be available here:  
  
https://www.nice.org.uk/guidance/indevelopment/gid-ta10485/documents

1. Date of the next meeting

The next meeting of the Technology Appraisal (Committee A) will be held on Tuesday 7 December and will start promptly at 9am.